Pfizer’s Copay Assistance Program considered an inducement of Medicare beneficiaries

March 14, 2023

The Supreme Court of the United States (SCOTUS) denied Pfizer’s petition to review the Second Circuit’s Court of Appeals ruling that found Pfizer in violation of the anti-kickback statute.  Two of Pfizer’s cardiac medications have a patient out-of-pocket cost of more than $1,000 per month.  The drug company, through its copay assistance program attempted to alleviate the financial burden of middle-income beneficiaries who did not qualify for low-income copay assistance.  Now that SCOTUS has decided not to review the Second Circuit’s ruling will stand.  Read Policy & Medicine’s article for links to the ruling & appeal and additional information.


Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to content